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month period were determined from a claims database.
Data were analyzed using Pearson correlation coefficients.
RESULTS: Results of the interim analysis in 150 respon-
dents (64 adults, 86 children) indicate that patient-
assessed severity had a stronger correlation with DLQI
(r = 0043, p = 0.0004) and CDLQI (r = 0042, p =
0.0011) than did retrospectively assessed severity (r =
0.39, p = 0.0015 [DLQI); and r = 0.10, P = 0044
[CDLQI)). Among the eight domains reported in the SF-
36, the DLQI showed the strongest correlation with the
mental health domain (r = -0.57, P = 0.0001). Visit
counts were significantly correlated with self-assessed se-
verity for adults (r = 0040) and children (r = 0.32).
CONCLUSIONS: A weaker correlation for QOL and
physician visits was observed with retrospectively as-
sessed severity than with patient-assessed severity. Self-
assessed severity of illness correlated moderately well
with QOL and number of physician encounters.
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Although OSHA regulations require that HBV be made
available to health care workers (HCW), the participa-
tion rate with the HBV policy is low. Previous studies ad-
dress characteristics of non-adhering HCW but do not
use this information to subsequently develop organiza-
tional strategies to increase adherence rates.
OBJECTIVE: Determine the vaccination rates of all high-
risk HCW to a HBV policy and to evaluate the effect of
leadership in improving those rates at a military hospital.
METHODS: 118 HCW at high risk for hepatitis B were
categorized by selected variables. Univariate analysis as-
sessed the significance of differences between HBV status
and the selected variables. A conditional probability
model evaluated the response to HBV policy and subse-
quent organizational leadership actions to improve vacci-
nation rates.
RESULTS: Only 61% and 56% of the military and civil-
ian HCW had initiated the HBV series; however, 100%
of the housekeepers completed the series. If a supervisor
had the HBV, the Odds Ratio that the HCW had the
HBV was 8.3 (95% CI 3.3, 21.1). The military HCW
completion rate was increased with passive then active
leadership to 85% then 100%. The civilian HCW com-
pletion rate was increased to 70% then 93%, with pas-
sive then active leadership actions during a six-month fol-
low-up observation period. Surprisingly, directed education
and worksite availability had no effect on the nursing
group. Leading reasons for civilian nurses initially declin-
ing HBV were pregnancy/nursing (36%), needle phobia
(28%), no knowledge of availability (21%), no time
(7%), and no risk perception (7%).
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CONCLUSION: Policy alone will not lead to acceptable
HBV rates among HCW. Acceptable rates are achievable
with both combined passive and active organizational
leadership techniques.
MGB.
FORMULARY IMPACT DECISION MODELING IN
HMG-COA REDUCTASE INHIBITORS
Corey R, Sung JCY
Novartis Pharmaceuticals Corp., East Hanover, NJ, USA
According to the NHANES III data, a majority of pa-
tients require 20-30% reduction in their LDL-cholesterol
to achieve their NCEP goal. Fluvastatin, a HMG-CoA re-
ductase inhibitor (statin), has been shown to be both safe
and effective in achieving 20-30% reductions in LDL-
cholesterol, and of all the statins, it has the lowest drug
acquisition cost.
OBJECTIVE: The purpose of this model was to assess the
economic impact of using a two-drug formulary that in-
cludes fluvastatin and another statin, versus a one-statin
formulary.
METHODS: In a hypothetical cohort of 10,000 patients,
a two-drug formulary with fluvasta tin as the statin of
choice for mild to moderate LDL-cholesterol reduction
and another agent for those patients requiring additional
reduction was compared with a one-drug formulary of
atorvastatin, pravastatin, or simvastatin. NHANES III
data was utilized to estimate the percentage of patients
requiring <30% or ;330% LDL-cholesterol reduction.
Doses used in this model were the average daily doses re-
quired for adequate LDL reduction as estimated by 1997
IMS data, and costs of drug therapy using a weighted
AWP. The cost savings was estimated by subtracting the
combined drug acquisition costs of the two statins from
the cost of a single statin prescribed for 100% of the pa-
tients. Sensitivity analyses were also performed on key
parameters of the model.
RESULTS: Based on NHANES III estimation, over 70% of
patients would require a <30% LDL-cholesterol reduction.
A two-drug formulary using fluvastatin was shown to pro-
vide more cost savings than a single-drug formulary using
any of the other agents, with annual cost difference ranging
from $1.2 million to $3 million per 10,000 patients.
CONCLUSIONS: Using formulary modeling, managed
care decision-makers can measure the economic impact of
their statin choice. This model demonstrates the economic
benefit of using fluvastatin in formulary management.
